A Repeat Buyer at This Gene Therapy Play, Near $950K
REGENXBIO is a clinical-stage biotech betting on gene therapies that deliver working genes into cells with genetic defects, and one of its officers just wrote a check for $949,381 at $9.25. This isn't his first time here, which matters more than the size. The tape is a mess though. Short and medium timeframes read sell, the long-term signal reads buy, and RSI sitting at 46 tells you the market hasn't made up its mind either. Support is right at $9.18, basically where he bought, so watch that line before you do anything.
The Filing
| Ticker | RGNX |
| Company | REGENXBIO Inc. |
| Insider | Gregory Austin Ciongoli |
| Buy amount | $949,381 |
| Filing date | August 27, 2026 |
| Conviction | Interesting · 51/100 |
| Setup type | Accumulation |
Ultimate members received this analysis in real time.